Aspirin or Clopidogrel as Monotherapy after 12 month DAPT

Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816. Courtesy of Dr. José Amadeo Guillermo Álvarez. The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug<a href="https://solaci.org/en/2016/02/04/aspirin-or-clopidogrel-as-monotherapy-after-12-month-dapt/" title="Read more" >...</a>

Different Options for Aspirin Hypersensitivity in PCI

Original Title: Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention. A Survey and Systematic Review. Reference: Bianco M et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002896. The follow up strategy for aspirin hypersensitive patients undergoing PCI remains unclear. A systematic search included 283 patients from 11 studies. Primary end point<a href="https://solaci.org/en/2016/01/28/different-options-for-aspirin-hypersensitivity-in-pci/" title="Read more" >...</a>

Low doses of aspirin for primary prevention in elderly patients with multiple risk factors.

Article The goal of this study was to assess the efficacy of low doses of aspirin (AAS) for primary prevention of cardiovascular events in Japanese elderly patients with multiple risk factors for arteriosclerosis but with no history of heart disease. This open study included patients between 60 and 85 with risk factors such as high<a href="https://solaci.org/en/2015/06/24/low-doses-of-aspirin-for-primary-prevention-in-elderly-patients-with-multiple-risk-factors/" title="Read more" >...</a>

POISE -2: Aspirin before a noncardiac surgery does not reduce the risk of death or myocardial infarction and increased bleeding.

There is great variability in the perioperative administration of aspirin (ASA) in patients undergoing noncardiac surgery, both those who had been receiving and those who not. This work included 10010 patients who planned to undergo noncardiac surgery and were randomized to aspirin versus placebo and clonidine versus placebo. Stratified according to whether they were receiving<a href="https://solaci.org/en/2015/06/24/poise-2-aspirin-before-a-noncardiac-surgery-does-not-reduce-the-risk-of-death-or-myocardial-infarction-and-increased-bleeding/" title="Read more" >...</a>

ADAPT-DES: Results at 1 year of the clinical impact of hypo-responders to aspirin and clopidogrel.

Background: The ADAPT-DES registry showed a strong correlation between hypo-responders to clopidogrel and the likelihood of stent thrombosis at 30 days, while the impact of aspirin response has not been evaluated so far. This presentation focuses on the aspirin response impact in the clinical course of one year. Methods and Results: A total of 8,583<a href="https://solaci.org/en/2015/06/24/adapt-des-results-at-1-year-of-the-clinical-impact-of-hypo-responders-to-aspirin-and-clopidogrel/" title="Read more" >...</a>

Resistance to Aspirin Associated to Greater Risk of In-Stent Thrombosis and Death

Original title: Aspirin Treatment and Outcomes After Percutaneous Coronary InterventionResults of the ISAR-ASPI Registry. Reference: Katharina Mayer et al. J Am CollCardiol. 2014;64(9):863-871. Aspirin administration, as part of the double antiagregation scheme, is essential in the context of PCI. The correlation between high platelet reactivity to on-clopidogrel treatment and higher events rates has been well established, while data<a href="https://solaci.org/en/2014/08/29/resistance-to-aspirin-associated-to-greater-risk-of-in-stent-thrombosis-and-death/" title="Read more" >...</a>

Aspirin, Clopidogrel and Warfarin. Is it safe or is a triple scheme necessary?

Original title: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Reference: Dewilde WJ et al. Lancet. 2013 Mar 30;381(9872):1107-15 The question to answer was simple, relevant, and is increasingly frequent in everyday practice: what to do when a patient who is anticoagulated has<a href="https://solaci.org/en/2013/05/10/aspirin-clopidogrel-and-warfarin-is-it-safe-or-is-a-triple-scheme-necessary/" title="Read more" >...</a>

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented.  The COMPARECrush looked at whether early and powerful<a href="https://solaci.org/en/2024/07/08/prehospital-crushed-vs-integral-prasugrel-in-stemi-patients-with-large-myocardial-area-at-risk/" title="Read more" >...</a>

Single Antiplatelet Therapy Following Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) has surged as an effective alternative to treat patients with atrial fibrillation (AF) presenting counterindications for oral anticoagulants. However, the optimal antithrombotic treatment after LAAO is still debated, seeing as it should prevent device related thrombosis (DRT) while minimizing bleeding risk.  The aim of this retrospective study carried out<a href="https://solaci.org/en/2024/05/01/single-antiplatelet-therapy-following-percutaneous-left-atrial-appendage-occlusion/" title="Read more" >...</a>

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.  This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>